Re: Erdafitinib in BCG-treated High-risk Non-muscleinvasive Bladder Cancer

被引：0
|
作者：
Duquesne, Igor [1 ]
de la Taille, Alexandre [1 ]
机构：
[1] Univ Paris Est Creteil, Henri Mondor Hosp, Dept Urol, Creteil, France
来源：
EUROPEAN UROLOGY | 2024年 / 85卷 / 01期
关键词：
PEMBROLIZUMAB;
D O I：
10.1016/j.eururo.2024.02.021
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：74 / 75
页数：2
相关论文
共 50 条
  • [21] Effect of Hypertension on Outcomes of High-Risk Patients After BCG-Treated Bladder Cancer A Single-Institution Long Follow-Up Cohort Study
    Dal Moro, Fabrizio
    Bovo, Alberto
    Crestani, Alessandro
    Vettor, Roberto
    Gardiman, Marina P.
    Zattoni, Filiberto
    MEDICINE, 2015, 94 (09) : e589
  • [22] A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
    Joshua, Julie Mariam
    Vijayan, Meenu
    Pooleri, Ginil Kumar
    THERAPEUTIC ADVANCES IN UROLOGY, 2019, 11 : 1 - 9
  • [23] Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non-muscleinvasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu ′erin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial.
    Necchi, Andrea
    Roumiguie, Mathieu
    Esen, Ahmet Adil
    Lebret, Thierry
    De Wit, Ronald
    Shore, Neal D.
    Bajorin, Dean F.
    Krieger, Laurence E. M.
    Kandori, Shuya
    Uchio, Edward M.
    Seo, Ho Kyung
    Boormans, Joost
    Kamat, Ashish M.
    Singer, Eric A.
    Grivas, Petros
    Nishiyama, Hiroyuki
    Nam, Kijoeng
    Kapadia, Ekta
    Van den Sigtenhorst-Fijlstra, Margot
    Kulkarni, Girish S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [24] TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients
    Batista, Rui
    Lima, Luis
    Vinagre, Joao
    Pinto, Vasco
    Lyra, Joana
    Maximo, Valdemar
    Santos, Lucio
    Soares, Paula
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [25] Low-dose bacille Calmette-Guerin for non-muscleinvasive bladder cancer: Results of a prospective study
    Nour, Hani H.
    Gobashy, Smair E.
    Kamal, Ahmad M.
    Elbaz, Ahmad G.
    Roshdy, Mamdouh A.
    Kamel, Ahmad I.
    ARAB JOURNAL OF UROLOGY, 2015, 13 (04) : 238 - 243
  • [26] CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients
    Castellano, Eva
    Samba, Celia
    Esteso, Gloria
    Simpson, Laura
    Vendrame, Elena
    Garcia-Cuesta, Eva M.
    Lopez-Cobo, Sheila
    Alvarez-Maestro, Mario
    Linares, Ana
    Leibar, Asier
    Ranganath, Thanmayi
    Reyburn, Hugh T.
    Martinez-Pineiro, Luis
    Blish, Catherine
    Vales-Gomez, Mar
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
    Huang, Haichao
    Jin, Jie
    Li, Xin
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2014, 30 (06) : 1432 - 1432
  • [28] Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease
    Miyake, Makito
    Nishimura, Nobutaka
    Fujii, Tomomi
    Fujimoto, Kiyohide
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (11) : 944 - 957
  • [29] TREATMENT PATTERN, MORTALITY AND COSTS AMONG BCG-TREATED NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS IN GERMANY
    Quignot, N.
    Doobaree, I
    Jiang, H.
    Lehmann, J.
    Ghatnekar, O.
    VALUE IN HEALTH, 2022, 25 (01) : S251 - S251
  • [30] A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer
    Ashish M Kamat
    Colin PN Dinney
    Nature Clinical Practice Urology, 2006, 3 : 472 - 473
12345